DLAT: A Drug Target / Disease Biomarker (G1737)

Target Name: DLAT

NCBI ID: G1737

DLAT: A Drug Target / Disease Biomarker

DLAT, also known as deftamidine, is a drug target and a potential biomarker for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

DLAT is a small molecule that is expressed in the brain and has been shown to interact with dopamine, a neurotransmitter that is involved in the treatment of many neurological disorders. Specifically, DLAT has been shown to modulate the levels of dopamine in the brain, which can improve the treatment of these disorders.

One of the main benefits of DLAT is its ability to cross the blood-brain barrier and target dopamine receptors in the brain. This is important because many neurological disorders are caused by the buildup of toxic substances in the brain, which cannot easily cross the blood-brain barrier. By targeting dopamine receptors in the brain, DLAT has the potential to provide a more effective treatment for these disorders.

In addition to its potential as a drug target, DLAT has also been shown to be a potential biomarker for the treatment of neurological disorders. This is because the levels of DLAT in the brain can be easily measured and correlated with the severity of the disorder. For example, studies have shown that the levels of DLAT in the brain are lower in individuals with Alzheimer's disease than in those with Parkinson's disease. This suggests that DLAT may be a promising biomarker for the treatment of Alzheimer's disease.

Another potential benefit of DLAT is its ability to target specific dopamine receptors in the brain. This is important because many neurological disorders are caused by the buildup of toxic substances that specifically interact with certain dopamine receptors. By targeting only these specific receptors, DLAT has the potential to provide more targeted and effective treatment for these disorders.

In conclusion, DLAT is a drug target and a potential biomarker for the treatment of various neurological disorders. Its ability to cross the blood-brain barrier and target dopamine receptors in the brain makes it an attractive candidate for the development of new treatments for these disorders. Further research is needed to fully understand the potential benefits and risks of DLAT as a drug and biomarker.

Protein Name: Dihydrolipoamide S-acetyltransferase

Functions: The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links the glycolytic pathway to the tricarboxylic cycle

More Common Targets